From the Department of Neurology (A.W., X.M., X.T., Y.Z., H.L., X.X., J.J., J.L., Y.W., X.Z., L.L., Z.L., Y.J., J.X., Y.W.), Beijing Tiantan Hospital, Capital Medical University, China; China National Clinical Research Center for Neurological Diseases (A.W., X.M., X.T., Y.Z., H.L., X.X., J.J., J.L., Y.W., X.Z., L.L., Z.L., Y.J., J.X., Y.W.), Beijing, China; Department of Epidemiology and Health Statistics (X.T.), School of Public Health, Capital Medical University, Beijing, China; Beijing Municipal Key Laboratory of Clinical Epidemiology (X.T.), China; Stroke Trials Unit, Mental Health & Clinical Neuroscience (P.M.B.), University of Nottingham, United Kingdom; Departments of Neurology (F.W.), Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China; Department of Neurology (W.C.), Xingyang People's Hospital, Henan, China; Department of Neurology (M.C.), Jingdezheng First People's Hospital, Jiangxi, China; Department of Neurology (J.L.), The First Hospital of Fangshan District, Beijing, China; Advanced Innovation Center for Human Brain Protection (A.W., X.M., Y.W.), Beijing Tiantan Hospital, Capital Medical University, China. yongjunwang@ncrcnd.org.cn.
Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass. Electronic address: tlaidlaw@partners.org.
From the Department of Neurology (A.W., X.M., X.T., Y.Z., H.L., X.X., J.J., J.L., Y.W., X.Z., L.L., Z.L., Y.J., J.X., Y.W.), Beijing Tiantan Hospital, Capital Medical University, China; China National Clinical Research Center for Neurological Diseases (A.W., X.M., X.T., Y.Z., H.L., X.X., J.J., J.L., Y.W., X.Z., L.L., Z.L., Y.J., J.X., Y.W.), Beijing, China; Department of Epidemiology and Health Statistics (X.T.), School of Public Health, Capital Medical University, Beijing, China; Beijing Municipal Key Laboratory of Clinical Epidemiology (X.T.), China; Stroke Trials Unit, Mental Health & Clinical Neuroscience (P.M.B.), University of Nottingham, United Kingdom; Departments of Neurology (F.W.), Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China; Department of Neurology (W.C.), Xingyang People's Hospital, Henan, China; Department of Neurology (M.C.), Jingdezheng First People's Hospital, Jiangxi, China; Department of Neurology (J.L.), The First Hospital of Fangshan District, Beijing, China; Advanced Innovation Center for Human Brain Protection (A.W., X.M., Y.W.), Beijing Tiantan Hospital, Capital Medical University, China.
From the Department of Neurology (A.W., X.M., X.T., Y.Z., H.L., X.X., J.J., J.L., Y.W., X.Z., L.L., Z.L., Y.J., J.X., Y.W.), Beijing Tiantan Hospital, Capital Medical University, China; China National Clinical Research Center for Neurological Diseases (A.W., X.M., X.T., Y.Z., H.L., X.X., J.J., J.L., Y.W., X.Z., L.L., Z.L., Y.J., J.X., Y.W.), Beijing, China; Department of Epidemiology and Health Statistics (X.T.), School of Public Health, Capital Medical University, Beijing, China; Beijing Municipal Key Laboratory of Clinical Epidemiology (X.T.), China; Stroke Trials Unit, Mental Health & Clinical Neuroscience (P.M.B.), University of Nottingham, United Kingdom; Departments of Neurology (F.W.), Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China; Department of Neurology (W.C.), Xingyang People's Hospital, Henan, China; Department of Neurology (M.C.), Jingdezheng First People's Hospital, Jiangxi, China; Department of Neurology (J.L.), The First Hospital of Fangshan District, Beijing, China; Advanced Innovation Center for Human Brain Protection (A.W., X.M., Y.W.), Beijing Tiantan Hospital, Capital Medical University, China.
From the Department of Neurology (A.W., X.M., X.T., Y.Z., H.L., X.X., J.J., J.L., Y.W., X.Z., L.L., Z.L., Y.J., J.X., Y.W.), Beijing Tiantan Hospital, Capital Medical University, China; China National Clinical Research Center for Neurological Diseases (A.W., X.M., X.T., Y.Z., H.L., X.X., J.J., J.L., Y.W., X.Z., L.L., Z.L., Y.J., J.X., Y.W.), Beijing, China; Department of Epidemiology and Health Statistics (X.T.), School of Public Health, Capital Medical University, Beijing, China; Beijing Municipal Key Laboratory of Clinical Epidemiology (X.T.), China; Stroke Trials Unit, Mental Health & Clinical Neuroscience (P.M.B.), University of Nottingham, United Kingdom; Departments of Neurology (F.W.), Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China; Department of Neurology (W.C.), Xingyang People's Hospital, Henan, China; Department of Neurology (M.C.), Jingdezheng First People's Hospital, Jiangxi, China; Department of Neurology (J.L.), The First Hospital of Fangshan District, Beijing, China; Advanced Innovation Center for Human Brain Protection (A.W., X.M., Y.W.), Beijing Tiantan Hospital, Capital Medical University, China.
From the Department of Neurology (A.W., X.M., X.T., Y.Z., H.L., X.X., J.J., J.L., Y.W., X.Z., L.L., Z.L., Y.J., J.X., Y.W.), Beijing Tiantan Hospital, Capital Medical University, China; China National Clinical Research Center for Neurological Diseases (A.W., X.M., X.T., Y.Z., H.L., X.X., J.J., J.L., Y.W., X.Z., L.L., Z.L., Y.J., J.X., Y.W.), Beijing, China; Department of Epidemiology and Health Statistics (X.T.), School of Public Health, Capital Medical University, Beijing, China; Beijing Municipal Key Laboratory of Clinical Epidemiology (X.T.), China; Stroke Trials Unit, Mental Health & Clinical Neuroscience (P.M.B.), University of Nottingham, United Kingdom; Departments of Neurology (F.W.), Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China; Department of Neurology (W.C.), Xingyang People's Hospital, Henan, China; Department of Neurology (M.C.), Jingdezheng First People's Hospital, Jiangxi, China; Department of Neurology (J.L.), The First Hospital of Fangshan District, Beijing, China; Advanced Innovation Center for Human Brain Protection (A.W., X.M., Y.W.), Beijing Tiantan Hospital, Capital Medical University, China.
From the Department of Neurology (A.W., X.M., X.T., Y.Z., H.L., X.X., J.J., J.L., Y.W., X.Z., L.L., Z.L., Y.J., J.X., Y.W.), Beijing Tiantan Hospital, Capital Medical University, China; China National Clinical Research Center for Neurological Diseases (A.W., X.M., X.T., Y.Z., H.L., X.X., J.J., J.L., Y.W., X.Z., L.L., Z.L., Y.J., J.X., Y.W.), Beijing, China; Department of Epidemiology and Health Statistics (X.T.), School of Public Health, Capital Medical University, Beijing, China; Beijing Municipal Key Laboratory of Clinical Epidemiology (X.T.), China; Stroke Trials Unit, Mental Health & Clinical Neuroscience (P.M.B.), University of Nottingham, United Kingdom; Departments of Neurology (F.W.), Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China; Department of Neurology (W.C.), Xingyang People's Hospital, Henan, China; Department of Neurology (M.C.), Jingdezheng First People's Hospital, Jiangxi, China; Department of Neurology (J.L.), The First Hospital of Fangshan District, Beijing, China; Advanced Innovation Center for Human Brain Protection (A.W., X.M., Y.W.), Beijing Tiantan Hospital, Capital Medical University, China.
From the Department of Neurology (A.W., X.M., X.T., Y.Z., H.L., X.X., J.J., J.L., Y.W., X.Z., L.L., Z.L., Y.J., J.X., Y.W.), Beijing Tiantan Hospital, Capital Medical University, China; China National Clinical Research Center for Neurological Diseases (A.W., X.M., X.T., Y.Z., H.L., X.X., J.J., J.L., Y.W., X.Z., L.L., Z.L., Y.J., J.X., Y.W.), Beijing, China; Department of Epidemiology and Health Statistics (X.T.), School of Public Health, Capital Medical University, Beijing, China; Beijing Municipal Key Laboratory of Clinical Epidemiology (X.T.), China; Stroke Trials Unit, Mental Health & Clinical Neuroscience (P.M.B.), University of Nottingham, United Kingdom; Departments of Neurology (F.W.), Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China; Department of Neurology (W.C.), Xingyang People's Hospital, Henan, China; Department of Neurology (M.C.), Jingdezheng First People's Hospital, Jiangxi, China; Department of Neurology (J.L.), The First Hospital of Fangshan District, Beijing, China; Advanced Innovation Center for Human Brain Protection (A.W., X.M., Y.W.), Beijing Tiantan Hospital, Capital Medical University, China.
From the Department of Neurology (A.W., X.M., X.T., Y.Z., H.L., X.X., J.J., J.L., Y.W., X.Z., L.L., Z.L., Y.J., J.X., Y.W.), Beijing Tiantan Hospital, Capital Medical University, China; China National Clinical Research Center for Neurological Diseases (A.W., X.M., X.T., Y.Z., H.L., X.X., J.J., J.L., Y.W., X.Z., L.L., Z.L., Y.J., J.X., Y.W.), Beijing, China; Department of Epidemiology and Health Statistics (X.T.), School of Public Health, Capital Medical University, Beijing, China; Beijing Municipal Key Laboratory of Clinical Epidemiology (X.T.), China; Stroke Trials Unit, Mental Health & Clinical Neuroscience (P.M.B.), University of Nottingham, United Kingdom; Departments of Neurology (F.W.), Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China; Department of Neurology (W.C.), Xingyang People's Hospital, Henan, China; Department of Neurology (M.C.), Jingdezheng First People's Hospital, Jiangxi, China; Department of Neurology (J.L.), The First Hospital of Fangshan District, Beijing, China; Advanced Innovation Center for Human Brain Protection (A.W., X.M., Y.W.), Beijing Tiantan Hospital, Capital Medical University, China.
From the Department of Neurology (A.W., X.M., X.T., Y.Z., H.L., X.X., J.J., J.L., Y.W., X.Z., L.L., Z.L., Y.J., J.X., Y.W.), Beijing Tiantan Hospital, Capital Medical University, China; China National Clinical Research Center for Neurological Diseases (A.W., X.M., X.T., Y.Z., H.L., X.X., J.J., J.L., Y.W., X.Z., L.L., Z.L., Y.J., J.X., Y.W.), Beijing, China; Department of Epidemiology and Health Statistics (X.T.), School of Public Health, Capital Medical University, Beijing, China; Beijing Municipal Key Laboratory of Clinical Epidemiology (X.T.), China; Stroke Trials Unit, Mental Health & Clinical Neuroscience (P.M.B.), University of Nottingham, United Kingdom; Departments of Neurology (F.W.), Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China; Department of Neurology (W.C.), Xingyang People's Hospital, Henan, China; Department of Neurology (M.C.), Jingdezheng First People's Hospital, Jiangxi, China; Department of Neurology (J.L.), The First Hospital of Fangshan District, Beijing, China; Advanced Innovation Center for Human Brain Protection (A.W., X.M., Y.W.), Beijing Tiantan Hospital, Capital Medical University, China.
From the Department of Neurology (A.W., X.M., X.T., Y.Z., H.L., X.X., J.J., J.L., Y.W., X.Z., L.L., Z.L., Y.J., J.X., Y.W.), Beijing Tiantan Hospital, Capital Medical University, China; China National Clinical Research Center for Neurological Diseases (A.W., X.M., X.T., Y.Z., H.L., X.X., J.J., J.L., Y.W., X.Z., L.L., Z.L., Y.J., J.X., Y.W.), Beijing, China; Department of Epidemiology and Health Statistics (X.T.), School of Public Health, Capital Medical University, Beijing, China; Beijing Municipal Key Laboratory of Clinical Epidemiology (X.T.), China; Stroke Trials Unit, Mental Health & Clinical Neuroscience (P.M.B.), University of Nottingham, United Kingdom; Departments of Neurology (F.W.), Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China; Department of Neurology (W.C.), Xingyang People's Hospital, Henan, China; Department of Neurology (M.C.), Jingdezheng First People's Hospital, Jiangxi, China; Department of Neurology (J.L.), The First Hospital of Fangshan District, Beijing, China; Advanced Innovation Center for Human Brain Protection (A.W., X.M., Y.W.), Beijing Tiantan Hospital, Capital Medical University, China.
From the Department of Neurology (A.W., X.M., X.T., Y.Z., H.L., X.X., J.J., J.L., Y.W., X.Z., L.L., Z.L., Y.J., J.X., Y.W.), Beijing Tiantan Hospital, Capital Medical University, China; China National Clinical Research Center for Neurological Diseases (A.W., X.M., X.T., Y.Z., H.L., X.X., J.J., J.L., Y.W., X.Z., L.L., Z.L., Y.J., J.X., Y.W.), Beijing, China; Department of Epidemiology and Health Statistics (X.T.), School of Public Health, Capital Medical University, Beijing, China; Beijing Municipal Key Laboratory of Clinical Epidemiology (X.T.), China; Stroke Trials Unit, Mental Health & Clinical Neuroscience (P.M.B.), University of Nottingham, United Kingdom; Departments of Neurology (F.W.), Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China; Department of Neurology (W.C.), Xingyang People's Hospital, Henan, China; Department of Neurology (M.C.), Jingdezheng First People's Hospital, Jiangxi, China; Department of Neurology (J.L.), The First Hospital of Fangshan District, Beijing, China; Advanced Innovation Center for Human Brain Protection (A.W., X.M., Y.W.), Beijing Tiantan Hospital, Capital Medical University, China.
From the Department of Neurology (A.W., X.M., X.T., Y.Z., H.L., X.X., J.J., J.L., Y.W., X.Z., L.L., Z.L., Y.J., J.X., Y.W.), Beijing Tiantan Hospital, Capital Medical University, China; China National Clinical Research Center for Neurological Diseases (A.W., X.M., X.T., Y.Z., H.L., X.X., J.J., J.L., Y.W., X.Z., L.L., Z.L., Y.J., J.X., Y.W.), Beijing, China; Department of Epidemiology and Health Statistics (X.T.), School of Public Health, Capital Medical University, Beijing, China; Beijing Municipal Key Laboratory of Clinical Epidemiology (X.T.), China; Stroke Trials Unit, Mental Health & Clinical Neuroscience (P.M.B.), University of Nottingham, United Kingdom; Departments of Neurology (F.W.), Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China; Department of Neurology (W.C.), Xingyang People's Hospital, Henan, China; Department of Neurology (M.C.), Jingdezheng First People's Hospital, Jiangxi, China; Department of Neurology (J.L.), The First Hospital of Fangshan District, Beijing, China; Advanced Innovation Center for Human Brain Protection (A.W., X.M., Y.W.), Beijing Tiantan Hospital, Capital Medical University, China.
Endometriosis is delineated as a benign yet steroid-dependent disorder characterized by the ectopic presence of endometrial glandular and stromal cells outside the uterine cavity, affecting estimated ...
We conducted a comprehensive search in the data available in...
The survey of the chosen terms revealed 72 articles, only 10 of which were considered for review....
Based on the research available currently, it is not substantial enough to address the conclusion that aspirin shall be an effective therapeutic choice for endometriosis, further studies are needed to...
Lipoprotein(a) [Lp(a)] is causally associated with cardiovascular diseases, and elevated levels are highly prevalent. However, there is a lack of available therapies to address Lp(a)-mediated risk. Th...
Aspirin has been demonstrated to have a clear benefit in secondary prevention of cardiovascular disease, but recent primary prevention trials have at best demonstrated a small benefit. However, indivi...
Individuals with elevated Lp(a) may benefit from aspirin therapy in primary prevention, but further study with plasma Lp(a) levels, broader populations, and randomization of aspirin are needed....
Pre-clinical models demonstrate that platelet activation is involved in the spread of malignancy. Ongoing clinical trials are assessing whether aspirin, which inhibits platelet activation, can prevent...
Urinary 11-dehydro-thromboxane B...
In total, 716 patients (breast 260, colorectal 192, gastro-oesophageal 53, prostate 211) median age 61 years, 50% male were studied. Baseline median U-TXM were breast 782; colorectal 1060; gastro-oeso...
Persistently increased thromboxane biosynthesis was detected after radical cancer therapy, particularly in colorectal and gastro-oesophageal patients. Thromboxane biosynthesis should be explored furth...
Hypersensitivity to aspirin is rare disorder occurring in 1.88% of the patients. Aspirin-hypersensitive patients requiring single antiplatelet agent may be treated with clopidogrel, an alternative ant...
ARTESiA (Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation) demonstrated that apixaban, compared with aspirin, significantly reduced stro...
To help inform decision making, the authors evaluated the efficacy and safety of apixaban according to baseline CHA...
We performed a subgroup analysis according to baseline CHA...
Baseline CHA...
One in 4 patients in ARTESiA with subclinical atrial fibrillation had a CHA...
Australian guidelines recommend 50-70 years consider taking aspirin to reduce their bowel cancer risk. We trialled a decision aid in general practice to facilitate the implementation of these guidelin...
Semistructured interviews were conducted with 17 participants who received the decision aid and 12 GPs who participated in the trial between June and November 2021. The interviews were coded inductive...
The study highlighted the dynamics of SDM for taking aspirin to prevent bowel cancer. Some participants discussed the decision aid with their GPs as advised prior to taking aspirin, others either took...
In summary, this study illustrated the complexities of SDM through using a decision aid in general practice to implement the guidelines for low-dose aspirin to prevent bowel cancer. While the decision...
ACTRN12620001003965....
To assess the impact of low-dose aspirin (LDA) starting in early pregnancy on delaying preterm hypertensive disorders of pregnancy....
Non-prespecified secondary analysis of a randomised masked trial of LDA....
The study was conducted among women in the Global Network for Women's and Children's Health's Maternal and Newborn Health Registry (MNHR) clusters, a prospective, population-based study in Kenya, Zamb...
Nulliparous singleton pregnancies between 6...
We compared the incidence of HDP at delivery at three gestational age periods (<28, <34 and <37 weeks) between women who were randomised to aspirin or placebo. Women were included if they were randomi...
Our primary outcome was pregnancies with HDP associated with preterm delivery (HDP@delivery) before <28, <34 and <37 weeks. Secondary outcomes included small for gestational age (SGA) <10th percentile...
Among the 11 976 pregnancies, LDA did not significantly lower HDP@delivery <28 weeks (relative risk [RR] 0.18, 95% confidence interval [CI] 0.02-1.52); however, it did lower HDP@delivery <34 weeks (RR...
In this secondary analysis of a study of low-risk nulliparous singleton pregnancies, early administration of LDA resulted in lower rates of preterm HDP and delivery before 34 and 37 weeks but not in t...
Capsule endoscopy (CE) has shown that low-dose aspirin occasionally causes small bowel (SB) bleeding. We herein evaluated the protective effects of mucoprotective agents (MPAs) on SB bleeding in aspir...
As CE is an insured procedure, we constructed an aspirin-SB cohort using NHIS claims data, with a maximum follow- up period of 24 months. Patients with anemia, melena, or hematochezia that occurred wi...
A total of 15,542 aspirin users were included. Anticoagulant use (hazard ratio [HR], 3.22), high Charlson comorbidity index score (≥ 2) (HR, 3.54), and PPI use (HR, 2.85) were significantly associated...
Eupatilin was associated with a reduced risk of SB bleeding in both aspirin users and those with concomitant use of acid suppressants. Eupatilin use should be considered for aspirin users, especially ...
Aspirin as a primary preventative in healthy older adults did not prolong disability-free survival in the ASPREE randomized trial. Observational studies following randomized trials allow assessment of...
Descriptive statistics compared health characteristics of those consented to ASPREE-XT at their first post-trial baseline (XT01) to corresponding ASPREE baseline values, and to those not consented. Li...
16,317 (93%) of the remaining and eligible 17,546 ASPREE participants were consented into ASPREE-XT; 14,894 completed XT01. Mean participant age had increased from 74.9 to 80.6 years. Overall health a...
The ASPREE-XT cohort was slightly less healthy at the XT01 visit than at ASPREE trial initiation, and rates of aspirin use without indication were similar to ASPREE baseline. Participants will be foll...
Daily low-dose aspirin increases major bleeding; however, few studies have investigated its effect on iron deficiency and anemia....
To investigate the effect of low-dose aspirin on incident anemia, hemoglobin, and serum ferritin concentrations....
Post hoc analysis of the ASPREE (ASPirin in Reducing Events in the Elderly) randomized controlled trial. (ClinicalTrials.gov: NCT01038583)....
Primary/community care in Australia and the United States....
Community-dwelling persons aged 70 years or older (≥65 years for Black persons and Hispanic persons)....
100 mg of aspirin daily or placebo....
Hemoglobin concentration was measured annually in all participants. Ferritin was measured at baseline and 3 years after random assignment in a large subset....
19 114 persons were randomly assigned. Anemia incidence in the aspirin and placebo groups was 51.2 events and 42.9 events per 1000 person-years, respectively (hazard ratio, 1.20 [95% CI, 1.12 to 1.29]...
Hemoglobin was measured annually. No data were available on causes of anemia....
Low-dose aspirin increased incident anemia and decline in ferritin in otherwise healthy older adults, independent of major bleeding. Periodic monitoring of hemoglobin should be considered in older per...
National Institutes of Health and Australian National Health and Medical Research Council....
